ES2049659A1 - Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena. - Google Patents

Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.

Info

Publication number
ES2049659A1
ES2049659A1 ES9202005A ES9202005A ES2049659A1 ES 2049659 A1 ES2049659 A1 ES 2049659A1 ES 9202005 A ES9202005 A ES 9202005A ES 9202005 A ES9202005 A ES 9202005A ES 2049659 A1 ES2049659 A1 ES 2049659A1
Authority
ES
Spain
Prior art keywords
alkyl
derivatives
activity
pharmaceutical composition
composition based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES9202005A
Other languages
English (en)
Other versions
ES2049659B1 (es
Inventor
Barker
Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Priority to ES9202005A priority Critical patent/ES2049659B1/es
Publication of ES2049659A1 publication Critical patent/ES2049659A1/es
Application granted granted Critical
Publication of ES2049659B1 publication Critical patent/ES2049659B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA A BASE DE DERIVADOS DE QUINA ZOLINA CON ACTIVIDAD ANTI-CANCERIGENA. COMPRENDE UN DERIVADO DE QUINAZOLINA DE FORMULA I, EN DONDE, POR EJEMPLO, R1 ES HIDROGENO, TRIFLUORMETILO O NITRO, N ES 1 Y R2 ES HALOGENO, TRIFLUORMETILO, NITRO, CIANO, ALQUILO 1-4C, ALCOXI 1-4C, N-ALQUIL(1-4C)AMINO, N,N-DI-[ALQUIL(1-4C)]AMINO, ALQUIL(1-4C)TIO, ALQUIL(1-4C) SULFINILO O ALQUIL(1-4C)SULFONILO; DILUYENTES O VEHICULOS FARMACEUTICAMENTE ACEPTABLES PARA TALES DERIVADOS; LOS NUEVOS DERIVADOS DE QUINAZOLINA Y UN PROCEDIMIENTO PARA SU PREPARACION; EL USO DE LAS PROPIEDADES INHIBIDORAS DE QUINASA TIROSINICA RECEPTORA DE LOS DERIVADOS DE QUINAZOLINA EN EL TRATAMIENTO DEL CANCER.
ES9202005A 1992-10-08 1992-10-08 Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena. Expired - Lifetime ES2049659B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9202005A ES2049659B1 (es) 1992-10-08 1992-10-08 Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9202005A ES2049659B1 (es) 1992-10-08 1992-10-08 Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.

Publications (2)

Publication Number Publication Date
ES2049659A1 true ES2049659A1 (es) 1994-04-16
ES2049659B1 ES2049659B1 (es) 1994-10-16

Family

ID=8278362

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9202005A Expired - Lifetime ES2049659B1 (es) 1992-10-08 1992-10-08 Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.

Country Status (1)

Country Link
ES (1) ES2049659B1 (es)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
JPS57144266A (en) * 1981-03-04 1982-09-06 Sankyo Co Ltd 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component
GB2160201A (en) * 1984-06-14 1985-12-18 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
GB2188319A (en) * 1986-03-27 1987-09-30 Ici Plc Anti-tumour quinazolines
WO1992014716A1 (en) * 1991-02-20 1992-09-03 Pfizer Inc. 2,4-diaminoquinazolines derivatives for enhancing antitumor activity
EP0520722A1 (en) * 1991-06-28 1992-12-30 Zeneca Limited Therapeutic preparations containing quinazoline derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
JPS57144266A (en) * 1981-03-04 1982-09-06 Sankyo Co Ltd 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component
GB2160201A (en) * 1984-06-14 1985-12-18 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
GB2188319A (en) * 1986-03-27 1987-09-30 Ici Plc Anti-tumour quinazolines
WO1992014716A1 (en) * 1991-02-20 1992-09-03 Pfizer Inc. 2,4-diaminoquinazolines derivatives for enhancing antitumor activity
EP0520722A1 (en) * 1991-06-28 1992-12-30 Zeneca Limited Therapeutic preparations containing quinazoline derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BASE DE DATOS JAPIO, 1980, Japan Patent Information Organization, Tokyo, Japón & JP-A-55038325 (SANKYO CO LTD) 17.03.1980 * Resumen * *
BASE DE DATOS JAPIO, 1982, Japan Patent Information Organization, Tokyo, Japón & JP-A-57144266 (SANKYO CO LTD) 06.09.1982 * Resumen * *

Also Published As

Publication number Publication date
ES2049659B1 (es) 1994-10-16

Similar Documents

Publication Publication Date Title
NO983707D0 (no) Kinazolin-derivater som antitumor-midler
FI922785A0 (fi) Terapeutiska preparat.
ATE152443T1 (de) Anilide-derivate
AR023706A1 (es) N-[4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il]-acrilamida, composiciones farmaceuticas que lo comprenden y uso comoinhibidor de cinasa de tirosina
AR024145A1 (es) Derivados de 5-fenil-pirimidina
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
ES8100276A1 (es) Un procedimiento para la preparacion de nuevos derivados de-4-anilinoquinazolinas
AR029400A1 (es) Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende
ES2108717T3 (es) Derivados de la tetrahidropirrolo(1,2-a)pirazina-4-espiro-3'-pirrolidina, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
AR009572A1 (es) Derivados de 3,4,5,6,7,8-hexahidro pirido (4',3':4,5) tieno (2,3-d) pirimidina sustituidos en posicion 3 y su uso
EA199800215A1 (ru) Бициклические производные 4-аралкиламинопиримидина как ингибиторы тирозинкиназы
PE20030867A1 (es) Derivados de quinazolinona
DE69711868D1 (de) Adenosin-derivate
AR031080A1 (es) Compuestos derivados de tiazolidindiona utiles como agentes antidiabeticos, procedimientos para la preparacion, composiciones farmaceuticas y usos en la fabricacion de medicamentos.
ES2049659B1 (es) Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
ES2070154T3 (es) Derivados de piridoindol y procedimientos para su preparacion.
MX9203692A (es) Preparaciones terapeuticas.
EP0302757A3 (en) Anti-emetic serotonin depleting agents
IT1250362B (it) Derivati dell'1-3-diossolano quali agenti per la riduzione del colesterolo
ES2102019T3 (es) 2,3,4,5-tetrahidro-1h-3-benzazepinas y sus sales de adicion farmaceuticamente aceptables.
DK0489767T3 (da) CCK-antagonister
ES2031889T3 (es) Un procedimiento para preparar un derivado de pirido (1,2-a)pirimidina.
IT1199339B (it) N-alchil derivati della 2-ammino-6,7-dimetossi tetralina,procedimenti per la loro preparazione e composizioni farmaceutiche ad attivita'an tiipertensiva che li contengono
IT1255219B (it) Derivati del tiadiazolo per la cura degli stati depressivi
ES2122982T3 (es) Derivados de tetrahidrocarbazol para la fabricacion de un medicamento para el tratamiento de una enfermedad en la que esta indicado un agonista similar a 5-ht1.